An observational study found that patients treated with nirmatrelvir-ritonavir for acute COVID-19 showed more frequent virologic rebound compared to those not receiving the treatment.
The first participant has been dosed in a Phase 3 study of Moderna's Flu-COVID vaccine candidate (mRNA-1083) in the US, according to the company.
The FDA approved the combination therapy—previously approved for certain metastatic melanoma patients—for the treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation.
Researchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read More
Members of the Advisory Committee on Immunization Practices voted 11-1 to recommend the maternal RSV vaccine for pregnant people to prevent RSV lower respiratory tract infection in infants.
Read More
Part of NIH’s STRIVE consortium, the therapeutic may prevent overactive immune systems from causing severe symptoms.
Read More
ACP issued four practice points on the pharmacologic and biologic treatment of COVID-19 in the outpatient setting, endorsing two drugs and advising against two others.
Read More
The health systems will prioritize improving vaccine rates among high-risk adults with lung disease across different populations.
Read More
The ongoing ACTIV-6 study found that fluvoxamine, even at increased dosages, offers no clinical benefit in treating mild-to-moderate COVID-19 symptoms.
Read More
Patients prescribed the FDA-recommended dose were significantly more likely to discontinue treatment over 180 days compared to those prescribed a higher dose, an NIH-supported study found.
Read More
An FDA advisory committee determined that phenylephrine, common in brands like Benadryl and Mucinex, is ineffective as a nasal decongestant.
Read More
A new study finds that idrevloride in hypertonic saline is safe and associated with a significant improvement in lung function in individuals with primary ciliary dyskinesia when compared to hypertonic saline alone.
Read More
The mRNA vaccines are formulated to more closely target currently circulating variants by including a monovalent component that corresponds to the Omicron variant XBB.1.5.
Read More
The FDA approved Moderna’s updated COVID-19 vaccine (Spikevax) for ages 12 years and above, and issued emergency use authorization for children age 6 months through 11 years old.
Read More
The American Lung Association has partnered with Sanofi to educate Americans about the flu and steps they can take to protect themselves from severe flu illness, with the goal of increasing vaccination rates.
Read More